Sean Duffy Sells 12,942 Shares of Omada Health (NASDAQ:OMDA) Stock

Omada Health, Inc. (NASDAQ:OMDA) CEO Sean Duffy sold 12,942 shares of Omada Health stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $24.81, for a total value of $321,091.02. Following the completion of the sale, the chief executive officer directly owned 411,861 shares in the company, valued at approximately $10,218,271.41. This represents a 3.05% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Omada Health Stock Down 0.7%

NASDAQ OMDA opened at $23.84 on Thursday. The firm’s 50 day moving average is $20.74 and its 200-day moving average is $16.38. The company has a market capitalization of $1.46 billion, a PE ratio of 476.80 and a beta of 1.73. Omada Health, Inc. has a 12-month low of $10.28 and a 12-month high of $26.92.

Omada Health (NASDAQ:OMDA) last released its earnings results on Thursday, August 6th. The company reported $0.08 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.10. Omada Health had a net margin of 1.39% and a return on equity of 2.67%. The business had revenue of $87.83 million during the quarter, compared to the consensus estimate of $80.93 million. As a group, sell-side analysts expect that Omada Health, Inc. will post -0.01 EPS for the current year.

Analyst Ratings Changes

Several brokerages recently commented on OMDA. Barclays increased their price target on Omada Health from $20.00 to $25.00 and gave the company an “overweight” rating in a research report on Monday, August 3rd. Wall Street Zen upgraded Omada Health from a “hold” rating to a “buy” rating in a research note on Saturday, August 8th. Robert W. Baird increased their price objective on Omada Health from $15.00 to $25.00 and gave the company a “neutral” rating in a report on Wednesday. BMO Capital Markets reissued an “outperform” rating and issued a $24.00 target price on shares of Omada Health in a research note on Friday, August 7th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $28.00 price target on shares of Omada Health in a research report on Friday, May 8th. Eleven research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $25.75.

More Omada Health News

Here are the key news stories impacting Omada Health this week:

• Positive Sentiment: Q2 results showed improving profitability and growth. Omada reported earnings of $0.08 per share versus the consensus estimate of a $0.02 loss, while revenue of approximately $87.8 million exceeded expectations of $80.9 million. The results suggest that the company’s digital chronic-care business is converting revenue growth into earnings. Omada Health: Q2 Shows More Evidence Of Growth Converting Into Earnings
• Positive Sentiment: Analyst price targets continue to rise. Robert W. Baird lifted its target from $15 to $25 while maintaining a neutral rating. Other recent targets include $27 from Citizens JMP and $35 from BTIG, contributing to a consensus “Moderate Buy” rating and an average target of $25.67.
• Neutral Sentiment: Baird’s neutral rating signals valuation concerns. Although the higher target implies additional upside, the firm’s hold-equivalent rating suggests that much of Omada’s improved earnings outlook may already be reflected in the stock’s valuation.
• Negative Sentiment: Multiple senior executives sold shares. CEO Sean Duffy sold a combined 21,570 shares, CFO Steven Cook sold 16,842 shares, President Wei-Li Shao sold 8,866 shares, and Chief Accounting Officer Craig Gracey sold 1,042 shares. The transactions totaled roughly $1.16 million and occurred at prices near $25. While insider sales may reflect personal or equity-compensation planning, the concentration of selling can weigh on sentiment because it reduces management ownership.

Institutional Investors Weigh In On Omada Health

Large investors have recently added to or reduced their stakes in the business. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Omada Health in the fourth quarter valued at $1,222,000. a16z Perennial Management L.P. acquired a new stake in shares of Omada Health during the 4th quarter worth about $2,480,000. Madryn Asset Management LP bought a new stake in shares of Omada Health during the 4th quarter worth about $9,212,000. Parallel Advisors LLC grew its stake in Omada Health by 12,235.9% in the 4th quarter. Parallel Advisors LLC now owns 123,359 shares of the company’s stock valued at $1,947,000 after buying an additional 122,359 shares during the last quarter. Finally, Walleye Capital LLC grew its stake in Omada Health by 677.2% in the 1st quarter. Walleye Capital LLC now owns 352,443 shares of the company’s stock valued at $4,430,000 after buying an additional 307,097 shares during the last quarter.

Omada Health Company Profile

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.